Notice of AGM

Oxford Cannabinoid Tech.Holdings

05 September 2023

 

Oxford Cannabinoid Technologies Holdings plc

("OCTP", or the "Company")

Notice of AGM and Form of Proxy

Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP) the pharmaceutical company developing prescription cannabinoid medicines, announces that its Notice of Annual General Meeting ("Notice") and Form of Proxy ("Proxy"), as well as its Annual Report and Accounts for the year ending 30 April 2023 ("AR&As") for shareholders who have opted to receive hard copies, have today been posted to shareholders.

Both the Notice of AGM and the Proxy will shortly be uploaded to the National Storage Mechanism and will be  available at: www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism. 

These documents, as well as the AR&As, are also available on the Company's website at: https://www.oxcantech.com/investors and in hard copy to shareholders upon request to the Company Secretary at Prama House, 267 Banbury Road, Oxford, England, OX2 7HT.

The Company's AGM will be held at the offices of Penningtons Manches Cooper LLP at 125 Wood Street, London EC2V 7AW on 28 September 2023 at 11.00a.m.

The Company is aware that the AGM gives shareholders the opportunity to ask the Board questions and encourages shareholders to submit any such questions in advance via email to the Company Secretary Rob Bennett at [e-mail]. Answers to questions received will be uploaded onto the Company website following the AGM.

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc	[phone]
Clarissa Sowemimo-Coker (CEO)	[e-mail]
Cairn Financial Advisers LLP
Emily Staples	[phone]
Jo Turner	[phone]
Axis Capital Markets Limited
Richard Hutchison	[phone]
Acuitas Communications	020 3745 0293 / 07799 767676
Simon Nayyar	[e-mail]
Arthur Dingemans	[e-mail]

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd (together the "Group"), a pharmaceutical Group developing prescription cannabinoid medicines initially targeting the U$ multi-billion global pain market.

OCTP currently has a portfolio of four drug development programmes. Its lead compound, OCT461201, will initially target neuropathic and visceral pain (including irritable bowel syndrome ("IBS") and chemotherapy induced peripheral neuropathy ("CIPN")), with Phase I clinical trials, aimed at demonstrating safety and tolerability. Trial results are expected in Q3 2023.  The global market for CIPN alone is currently forecast to reach US$1.17bn by 2028.

OCTP's drug development pipeline comprises both natural and synthetic compounds, and includes compounds targeting trigeminal neuralgia, a severe type of face pain, and cannabinoid derivatives targeting pain and potentially other therapeutic areas. Having established an exclusive license agreement with Canopy Growth Corporation for their entire pharmaceutical cannabinoid derivative library, OCTP now has a portfolio of almost five hundred derivatives and intellectual property rights including fourteen patent families and associated research data.

OCTP has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence. OCTP's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

END